| This week's sponsor is Premier Research. | |  | Beating the Odds in Early-Phase Oncology Trials
Despite advances in molecular targeting, developing new cancer drugs remains a long shot. Read our white paper for insights on maximizing early-phase trial success. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Monday, February 5, 2018 Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a Bloomberg report that it is exploring strategic options for the business. |
|
|
| This week's sponsor is Dell EMC. | |  | [Webinar] Is Your Life Science Data "F-A-I-R"?
Tuesday, February 13 | 2pm ET / 11am PT
Is Your Life Science Data "F-A-I-R"? Join DataFrameworks & Dell EMC in this webinar to discover a new approach to create scientific data that is findable, accessible, interoperable, and reusable. Register now! |
Top Stories Monday, February 5, 2018 Just a few days after the FDA placed a clinical hold on its lead cell therapy for cancer, Bellicum Pharma has added new R&D leadership by appointing ex-Genentech executive William Grossman, M.D., Ph.D., as its chief medical officer. Monday, February 5, 2018 ReViral has hit its primary and secondary endpoints in a small midstage trial testing its experimental medication against the respiratory syncytial virus (RSV). Monday, February 5, 2018 While biopharma companies are investing more than ever to develop innovative therapies, returns are not keeping pace. How can emerging technologies help improve productivity? Learn more from Deloitte’s annual ROI analysis. Monday, February 5, 2018 Charles River Laboratories has strengthened its high-throughput screening capabilities by gaining access to technologies available at AstraZeneca’s Centre for Lead Discovery in Cambridge, U.K. Monday, February 5, 2018 Intarcia slashed 60 jobs in a restructuring scheme following the FDA's rejection of its drug-device treatment for Type 2 diabetes. Monday, February 5, 2018 After ushering Juno Therapeutics through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set to take home up to $287 million when the CAR-T player seals its buyout with Celgene. Monday, February 5, 2018 Bristol-Myers Squibb finally got its win in first-line lung cancer—and it’s a success that not only helps confirm one immunotherapy combo approach that has been in doubt, but puts forward a diagnostic biomarker that could apply to other cancer types. | This week's sponsor is IQVIA. | |  | Discover a new path to your success via Human Data Science. IMS Health and Quintiles are now IQVIA™ – created to advance your pursuits of human science by unleashing the power of data science and human ingenuity. Join the journey today. Learn More. |
Resources Sponsored by: RBC Wealth Management Guiding corporate executives through regulatory complexities, while delivering an array of sophisticated investment options. Learn more. Sponsored by: Seton Hall Don’t miss this educational program trusted by multi-national companies as part of their employee’s compliance training. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating in the Asia-Pacific region. Visit event page for session topics. Presented by: Patheon Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties. Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? Join this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue. Sponsored by: Veeva Systems Expanding into new markets places a spotlight on inefficient processes. Sponsored by: Veeva Systems Regulatory leaders share challenges and best practices from a lack of standardization, manual processes, and fragmented systems. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
